#USA #New York #CancerCare #340B Program #Pioneer Institute

Study Findings on Financial Assistance in 340B and Non-340B Hospitals

In a recently published study by CancerCare® in collaboration with the Pioneer Institute, significant disparities between 340B and non-340B hospitals regarding financial assistance provided to patients have been unveiled. The study critically examined 2023 data from the RAND Corporation, which encompassed around 3,999 hospitals nationwide, revealing that 340B hospitals typically extend less direct financial support in terms of charity and uncompensated care compared to their non-340B counterparts.

The central aim of the 340B program is to enhance access to healthcare services for low-income and uninsured individuals. However, the findings from this research raise serious concerns about whether the program meets its fundamental objectives. According to Robert Popovian, PharmD, MS, a Senior Visiting Fellow at Pioneer Institute, the study indicates that the anticipated benefits of the 340B program are not being realized across the board.

Key Insights from the Study

The results showed that 340B hospitals not only provided lower average charity care but also offered less uncompensated care to those in need compared to non-340B hospitals. This observation becomes even more perplexing considering that 340B hospitals engaged slightly more with Medicaid patients. The anticipated savings from the program, intended to be invested back into patient care, are not being optimized, giving rise to skepticism about the program’s efficacy.

William Smith, PhD, a Senior Fellow at Pioneer Institute, articulated the core issue stating, “340B was designed to expand access for low-income and uninsured patients, but now it is contributing to a complex financial landscape where some hospitals are profiting significantly while failing to provide adequate support to their communities.” This disparity indicates that the program, originally aimed at assisting underserved populations, might be creating unintended consequences where financial gains are prioritized over patient care.

Implications for Patients

CancerCare's Vice President of Policy, Kim Czubaruk, JD, shared insights from conversations with patients who navigate significant financial and access barriers to receive cancer treatment. “The essence of the 340B program is for hospitals to utilize savings from drug discounts to deliver comprehensive services to a larger pool of vulnerable patients. As it stands, the unmet need for accessible cancer care is alarming,” Czubaruk noted. She emphasizes that it’s crucial for federal reforms to be initiated to ensure that the 340B program fulfills its foundational purpose and serves to enhance patient access to necessary treatments.

Need for Reforms

The study evidently suggests a dire need for reforms that enhance transparency and accountability for 340B hospitals. Hospitals should be incentivized to redirect the substantial revenue generated from the program back into the community they serve, particularly focusing on enhancing charity care levels. Without such reforms, the initial objectives of the 340B program remain at risk of being undermined, leaving numerous patients struggling to find affordable care.

Conclusion

The CancerCare® and Pioneer Institute study sheds light on critical aspects of the 340B program, highlighting financial discrepancies that ultimately affect patient care. As discussions about healthcare accessibility and affordability continue, it becomes increasingly important for policymakers to ensure that the benefits of initiatives like the 340B program genuinely translate into improved care for those who need it most. Awareness, advocacy, and reform are essential to uphold the intended purpose of supporting low-income and uninsured patients effectively.

For the complete study, please visit here.